Cost-effectiveness of alternative treatments for women with osteoporosis in Canada

References

• Hanley DA, Josse RG. Introduction. In: Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada [special supplement]. Can Med Assoc J 1996;155:921–3
   Google Scholar
• Osteoporosis Canada; www.osteoporosis.ca. 2006
   Google Scholar
• National Institute of Health Osteoporosis and Related Bone Diseases – National Resource Centre; www.osteo.org. 2006
   Google Scholar
• National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
   Google Scholar
• Goeree R, O’Brien B, Pettitt D, et al. An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynecol 1996;18(Suppl July 15):15–24
   Google Scholar
• Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the national osteoporosis foundation. J Bone Miner Res 1997;12:24–35
   PubMed Web of Science ®Google Scholar
• Phillilps S, Fox N, Jacobs J, et al. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988;9:271–9
   PubMed Web of Science ®Google Scholar
• National Institute of Health Osteoporosis and Related Bone Diseases – National Resource Centre; www.osteo.org. 2006
   Google Scholar
• National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
   Google Scholar
• Riggs BL, Melton III LJ. The world wide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505S–11S
   Google Scholar
• National Institute of Health Osteoporosis and Related Bone Diseases – National Resource Centre; www.osteo.org. 2006
   Google Scholar
• National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
   Google Scholar
• National Institute of Health Osteoporosis and Related Bone Diseases – National Resource Centre; www.osteo.org. 2006
   Google Scholar
• National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
   Google Scholar
• Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001–5
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporosis Int 2000;11(7):556–61
   PubMed Web of Science ®Google Scholar
• Josse RG. Osteoporosis. A modern plague: widespread, expensive and too often deadly. Can Pharm J 1989;122:460–8
   Google Scholar
• Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998;8 (Suppl. 4):S1–S88
   Google Scholar
• Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. New Engl J Med 1980;303:1195–8
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin S, Pettitt DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–36
   PubMed Web of Science ®Google Scholar
• Kiel DP, Felson DT, Anderson JJ, et al. Hip fractures and the use of estrogens in postmenopausal women. The Framingham Study. New Engl J Med 1987;317:1169–74
   PubMed Web of Science ®Google Scholar
• Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy in older women. Ann Intern Med 1995;122:9–16
   PubMed Web of Science ®Google Scholar
• van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998;37:87–94
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgström F, Johnell OOASD, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis Int 2005;16:15–25
   PubMed Web of Science ®Google Scholar
• Borgström F, Johnell O, Kanis JA, et al. Cost-effectiveness of raloxifene treatment of osteoporosis in Sweden. Pharmaco-economics 2004;22:1153–65
   Google Scholar
• Stevenson M, Jones ML, DeNigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technology Assessment NHS R&D HTA Programme; 2005. Report No. 22, vol 1
   Google Scholar
• Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment NHS R&D HTA Programme; 2002. Report No. 6, vol 29
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. J Am Med Assoc 2002;287:847–57
   Google Scholar
• Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125–34
   PubMed Web of Science ®Google Scholar
• Delmas P, Ensrud K, Adachi J, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609–17
   PubMed Web of Science ®Google Scholar
• Papadimitropoulos EA, Coyte PC, Josse RG, et al. Current and projected rates of hip fracture in Canada. Can Med Assoc J 1997;157:1357–63
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000;27:585–90
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures [Study of Osteoporotic Fractures Research Group]. J Bone Miner Res 1999;14:821–8
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton III LJ. Involutional osteoporosis. New Engl J Med 1986;314:1676–86
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996;312:1254–9 [also selected for review in American College of Physicians Journal Club, 1996 September/October: 48. Br Med J 1996;312: 1254–9]
   Google Scholar
• Kannel WB, Wolf PA, Garrison RJ. The Framingham Study: an epidemiological investigation of cardiovascular disease. US Department of Health & Human Services 1987; NIH Publication 87–2284
   Google Scholar
• Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585–93
   PubMed Web of Science ®Google Scholar
• Statistics Canada CANSIM Database. Table 102–0525, deaths, by cause – chapter V: mental and behavioural disorders (F00-F99), age group and sex, Canada, annual. Available from: http://estat. statcan.ca/ 2005 May 18 [last accessed: 2005 July 15]
   Google Scholar
• Statistics Canada CANSIM Database. Table 102–0540, deaths, by cause – chapter XX: external causes of morbidity and mortality (V01-Y89), age group and sex, Canada, annual. Available from: http://estat.statcan.ca/ 2005 May 18 [last accessed: 2005 July 15]
   Google Scholar
• Wiktorowicz M, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteo Int 2001;12(4):271–8
   Google Scholar
• Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 1999;159:1215–20
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999;159:445–53
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health. Ontario drug benefit formulary/comparative drug index. Available from: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html 2005
   Google Scholar
• Ontario Ministry of Health and Long Term Care. Ontario health insurance plan (OHIP). Available from: http://www.health.gov.on.ca/english/public/program/ohip/ohip_mn.html 2005. [last accessed: 2005 October 10]
   Google Scholar
• The 1996 Pharmacy Business Trends Report. Toronto; 1998
   Google Scholar
• Ontario Ministry of Health and Long Term Care. Schedule of benefits for physician services under the Health Insurance Act. 2005, Ottawa, Canada
   Google Scholar
• Ontario Ministry of Health and Long Term Care. Ontario health insurance plan (OHIP) 2005. Available at: http://www.health.gov.on.ca/english/public/program/ohip/ohip_mn.html), [accessed November 14, 2005]
   Google Scholar
• Anon. Ontario case cost project (OCCP): Ontario guide to case costing, version 1.1. September ed. Ottawa: Ontario Case Cost Project; 1995
   Google Scholar
• Ontario case costing initiative (OCCI). Available at: http://www.occp.com [accessed November 14, 2005]
   Google Scholar
• Statistics Canada CANSIM Database. Table 326–0002, consumer price index (CPI), 2001 basket content, annual. Available from: http://estat.statcan.ca/ 2005 April 2 [last accessed 2005 September 13]
   Google Scholar
• Will BP, Birthelot J, Houle C. A model for estimating the cost and burdens of breast cancer diagnosis and treatment in Canada. Health Reports 1993;5:399–408
   Google Scholar
• Eli Lilly clinical study synopsis (study H3S-MC-GGGK). Comparison of raloxifene hydrochloride and placebo in the treatment of postmenopausal women with osteoporosis. Data on file 2000
   Google Scholar
• Tosteson A, Gabriel S, Grove M, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporosis Int 2001;12:1042–9
   PubMed Web of Science ®Google Scholar
• Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardio 1991;67:1084–9
   PubMed Web of Science ®Google Scholar
• Nease RF, Kneeland T, O’Connor GT, et al. Variations in patient utilities for outcomes of the management of chronic stable angina. J Am Med Assoc 1995;273:1185–90
   Google Scholar
• Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9 (Suppl 2):8–22
   PubMedGoogle Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Assoc 1997;4:49–56
   Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996
   Google Scholar
• Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak 1998;18(Suppl):S65–S80
   Google Scholar
• Microsoft Office Online. Microsoft Excel, 2003. Available from: http://office.microsoft.com/ 2003 [last accessed: 2005 October 10]
   Google Scholar
• TreeAge Pro, 2005. Available at: http://www.treeage.com/products/index.html
   Google Scholar
• Statistics Canada. Life Expectancy. 2005. Available at: http://www40.statcan.ca/l01/cst01/health26.htm
   Google Scholar
• Drummond MF, Sculpher MJ, O’Brien BJ, et al. Methods for economic evaluation of health care programmes, 3rd ed. Oxford: Oxford University Press; 2005
   Google Scholar
• Stavraky KM, Collins JA, Donner A, et al. A comparison of estrogen use by women with endometrial cancer, gynecologic disorder, and other illnesses. Am J Obstet Gynecol 1981;141: 547–55
   PubMed Web of Science ®Google Scholar
• LaVecchia C, Franceschi S, Decarli A, et al. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984;73:667–71
   PubMed Web of Science ®Google Scholar
• Shapiro S, Kelly J, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discounted use of conjugated estrogens. New Engl J Med 1985;313:969–72
   PubMed Web of Science ®Google Scholar
• Buring J, Bain C, Ehrmann R. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434–41
   PubMed Web of Science ®Google Scholar
• Ewertz M, Schou G, Boice J. The joint effect of risk factors on endometrial cancer. Eur J Cancer Clin Oncol 1988;24:189–94
   PubMedGoogle Scholar
• Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 1993;81:265–71
   PubMed Web of Science ®Google Scholar
• Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20–4
   Google Scholar
• Levi F, LaVecchia C., Gulie C, et al. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 1993;29:1445–9
   Google Scholar
• Rubin G, Peterson H, Lee N, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148–54
   PubMed Web of Science ®Google Scholar
• Voigt L, Weiss N, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274–7
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of exogenous hormones and risk of endometrial cancer [abstract]. Am J Epidemiol 1986;124:520
   Web of Science ®Google Scholar
• Petitti D, Perlman J, Sidney S. Noncontraceptive estrogens and mortality: longterm follow-up of women in the Walnut Creek study. Obstet Gynecol 1987;70:289–92
   Google Scholar
• Paganini-Hill A, Ross R, Henderson B. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445–7
   Google Scholar
• Henderson B, Paganini-Hill A, Ross R. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–8
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:1–10
   PubMedGoogle Scholar
• Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1993;148:913–7
   Google Scholar